NF-κB信号通路在恶性肿瘤化疗耐药中的作用

doi:10.11904/j.issn.1002-3070.2021.06.019

Abstract

Abstract: Malignant tumors have become the main reason affecting people′s health.Chemotherapy is one of the most widely used and most effective anti-tumor treatments.However,with the use of chemotherapeutic drugs,tumor cells will develop drug resistance,which becomes the main reason that affects the effect of chemotherapy.The emergence of drug resistance may involve many mechanisms,including abnormal cell cycle regulation,blockage of apoptotic signaling pathways,and abnormal expression of drug resistance genes.Recent studies have shown that cell survival signaling pathways play an important role in tumor chemotherapy resistance.The abnormality of nuclear factor kappa B(NF-κB)signaling pathway is one of the main mechanisms of drug resistance in malignant tumors.Therefore,NF-κB signaling pathway may also become an effective target for overcoming drug resistance in malignant tumors.This review briefly summarizes the role of NF-κB signaling pathway in chemotherapy resistance of malignant tumors and its research progress.

Key words: NF-κB, Signaling pathway, Cancer, Chemotherapy resistance

CLC Number:

LI Na, DENG Qian, JIANG Jianjun. The role of NF-κB signaling pathway in chemotherapy resistance of malignant tumors[J]. Journal of Practical Oncology, 2021, 35(6): 580-584.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.06.019

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I6/580

References

1 Goldstein LJ,Galski H,Fojo A,et al.Expression of a multidrug resistance gene in human cancers[J].J Natl Cancer Inst,1989,81(2):116-124.
2 Cho H,Thorvaldsen JL,Chu Q,et al.Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice[J].Biol Chem,2001,276(42):38349-38352.
3 Kim CK,Nguyen TL,Lee SB,et al.Akt2 and nucleophosmin/B23 function as an oncogenic unit in human lung cancer cells[J].Exp Cell Res,2011,317(7):966-975.
4 Arsura M,Cavin LG.Nuclear factor-kappaB and liver carcinogenesis[J].Cancer Lett,2005,229(2):157-169.
5 Baumgartner B,Weber M,Quirling M,et al.Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts[J].Leukemia,2002,16(10):2062-2071.
6 Xue YS,Yang L,Li JZ,et al.Combination chemotherapy with Zyflamend reduced the required resistance of bladder cancer cels to cisplatin through inhibiting NF-κB signaling pathway[J].Onco Targets Ther,2018,11:4413-4429.
7 Hafsi S,Pezzino F,Candido S,et al.Gene alterations in the Pl3K/PTEN/AKT pathway as a mechanism of drug-resistance(review)[J].Int J Oncol,2012,40(3):639-644.
8 Riquelme I,Tapia O,Espinoza JA,et al.The gene expression status of the Pl3K/AKT/mTOR pathway in gastric cancer tissues and cell lines[J].Pathol Oncol Res,2016,22(4):797-805.
9 Bacheru U,Kern W,Hafe R,et al.Cyclin D1(CCND1)messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma[J].Exp Hematol,2013,41(12):1028-1037.
10 黄虎,栗娜,杨柳,等.非小细胞肺癌组织中NF-κB和CyclinD1及p27表达与患者化疗敏感性[J].贵州医科大学学报,2019,44(2):195-199.
11 Sheng YH,Choa P,Lourie R,et al.MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance[J].Int J Cancer,2017,140(10):2351-2363.
12 Bidwell GL,Raucher D.Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc[J].Biochem Pharmacol,2006,71(3):248-256.
13 Mohammad S,Ava SA,Atieh PS,et al.c-Myc inhibition using 10058-F4 increased the sensitivity of acute promyelocytic leukemia cells to arsenic trioxide via blunting PI3K/NF-κB[J].Arch Med Res,2020,51(7):636-644.
14 Sun D,Wang X,Sui GQ,et al.Downregulation of mi R-374b-5p promotes chemotherapeutic resistance in pancreatic cancer by upregulating multiple anti-apoptotic proteins[J].Int J Oncol,2018,52(5):1491-1503.
15 Raˇckauskas R,Zhou DC,selis S,et al.Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins[J].Oncol Rep,2017,37(6):3660-3666.
16 Semba S,Trapasso F,Fabbri M,et al.Fhit modulation of the Akt-survivin pathway in lung cancer cells:Fhit-tyrosine 114(Y114)is essential[J].Oncogene,2006,25(20):2860-2872.
17 Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
18 Piovani G,Savio G,Traversa M,et al.De novo 1Mb interstitial deletion of 8p22 in a patient with slight mental retardation and speech delay[J].Mol Cytogenet,2014,7:25.
19 武潮.MicroRNA-383调控非小细胞肺癌细胞对顺铂敏感性的作用及机制研究[D].重庆:西南大学,2020.
20 Huang RS,Zheng YL,Zhao J,et al.microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling[J].Biomed Pharmacother,2018,98:538-544.
21 Wang ZY,Wang N,Liu PX,et al.MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells,a process modulated by the natural autophagy inducer isoliquiritigenin[J].Oncotarget,2014,5(16):7013-7026.
22 Yang HL,Zheng YC,Zhang YZ,et al.Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling[J].Leuk Res,2017,60:82-88.
23 Zhang LH,Yang AJ,Wang M,et al.Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells[J].Apoptosis,2016,21(4):473-488.
24 Zhou Y,Uddin S,Zimmerman T,et al.Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3[J].Leuk Lymphoma,2008,49(10):1945-1953.
25 Kroemer G,Pouyssegur J.Tumor cell metabolism:cancer′s Achilles′ heel[J].Cancer Cell,2008,13(6):472-482.
26 Fritz V,Fajas L.Metabolism and proliferation share common regulatory pathways in cancer cells[J].Oncogene,2010,29(31):4369-4377.
27 Liu T,Wei RD,Zhang YT,et al.Association between NF-κB expression and drug resistance of liver cancer[J].Oncol Lett,2019,17(1):1030-1034.
28 Chen Q,Liu X,Luo Z,et al.Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression[J].J Cell Physiol,2019,234(5):6611-6623.
29 赵宝霞,刘思琪,董思聪,等.Bmi-1 介导的 K562/ADR 细胞多药耐药机制[J].中国实验血液学杂志,2020,28(3):758-766.
30 王子元,孙明瑜,陈佳,等.健脾解毒方通过NF-κB/Nrf2/MRP2信号通路逆转大肠癌多药耐药的作用机制[J].中华中医药杂志,2020,35(7):3367-3371.
31 Lin X,Zhang X,Wang Q,et al.Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line[J].Neoplasma,2012,59(3):248-256.
32 Muthusamy G,Gunaseelan S,Prasad NR.Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-κB signaling pathway[J].J Nutr Biochem,2019,63:62-71.
33 赵宝霞,刘思琪,董思聪,等.Bmi-1 介导的 K562/ADR 细胞多药耐药机制[J].中国实验血液学杂志,2020,28(3):758-766.
34 杜国良,赵宗茂,宋建抢,等.核转录因子-κB抑制剂逆转胶质瘤细胞株对替莫唑胺的耐药性[J].中华实验外科杂志,2018,35(8):1476-1478.
35 Qiu YX,Dai Y,Zhang C.et al.Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma:a targeted intervention of 14-3-3η/NF-κB feedback loop[J].J Exp Clin Cancer Res,2018,37(1):321.
36 刘俊峰,谢涛,刘羽,等.核因子-κB抑制剂对胶质瘤干细胞放疗增敏的作用[J].中华实验外科杂志,2018,35(9):1684-1686.

[1]	LIU Rui, CHEN Yang, SHI Qingping, YU Qiuli, ZHU Yunfang, WEN Hongmei. Characteristics and time trend of thyroid cancer incidence and mortality from 2012 to 2016 in cancer registration areas of Yunnan province [J]. Journal of Practical Oncology, 2021, 35(6): 489-494.
[2]	WU Liting, LI Dabing, DENG Xiaoxia, LI Baisong. Trend and prediction of gastric cancer burden in Beibei district of Chongqing city from 2013 to 2020 [J]. Journal of Practical Oncology, 2021, 35(6): 495-499.
[3]	LUO Wen, JIA Li, ZHANG Jiawen, WANG Dongjie, KONG Yingjun. The effects of circRNA MYO1C on lung cancer cell autophagy and cancer stem cell differentiation [J]. Journal of Practical Oncology, 2021, 35(6): 500-505.
[4]	WANG Lina, WANG Le, JIN Hong, LI Qi, CHENG Haiyan. The expression of UBQLN1 in cervical cancer and its effect on prognosis [J]. Journal of Practical Oncology, 2021, 35(6): 506-510.
[5]	CHEN Yixin, SUN Yihua, CHENG Yangyang, HE Kaitong, GUO Ting. Relationship between preoperative inflammation-related indicators and prognosis of patients with resectable gastric cancer [J]. Journal of Practical Oncology, 2021, 35(6): 517-522.
[6]	LUO Bo, ZHANG Qu, ZHENG Hongmei, LIANG Xinjun, ZHOU Xiaomei, WU Xinhong. Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis [J]. Journal of Practical Oncology, 2021, 35(6): 523-528.
[7]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.
[8]	MU Guannan, MA Qiang. The role of NK cell polarization in endometrial cancer [J]. Journal of Practical Oncology, 2021, 35(6): 534-537.
[9]	ZHAO Xuan, LI Guodong, LIU Ming. Research progress of metallothionein in colorectal cancer [J]. Journal of Practical Oncology, 2021, 35(6): 538-541.
[10]	WANG Langyue, ZHAO Qi, WU Huaxing. New progress in the regulation of colorectal cancer by metabolites derived from gut microbiota [J]. Journal of Practical Oncology, 2021, 35(6): 547-551.
[11]	YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 552-556.
[12]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[13]	ZHOU Tianhong, GU Xiuying, YAO Fang, SONG Shuming. Analysis for screening results of breast cancer in Urumqi from 2014 to 2018 [J]. Journal of Practical Oncology, 2021, 35(5): 391-395.
[14]	FU Yan¹, YAN Lili², WANG Chunyu², FU Fangmin², DONG Hua³. Analysis for the prevalence of malignant tumors in Qionghai city from 2010 to 2016 [J]. Journal of Practical Oncology, 2021, 35(5): 396-401.
[15]	MA Buhuan¹, LIU Caixia². Research progress of Jagged1 promoting the occurrence,development and distant metastasis of breast cancer [J]. Journal of Practical Oncology, 2021, 35(5): 452-457.

The role of NF-κB signaling pathway in chemotherapy resistance of malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments